A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 14012 participants.
Also called NCT05739383
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 14,012 participants
- Sponsor
- Registry
-
NCT05739383
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Greece, Hong Kong SAR China, Hungary, India, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Philippines, Poland, Portugal, Puerto Rico, Romania, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05739383. Randomized; quadruple masking; primary purpose prevention. Start 2023-03-09 (actual); primary completion 2029-04-16 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
- Condition
- Primary Prevention of Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Intervention (Drug)
- Placebo in 1.5ml
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05739383- Content hash
e046bd998abb2e4c988c5ea3119d068ed32fdeed33305554651fb1334c430604